Smith & Nephew plc (BVMF:S1NN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 67.96B -4.9% |
| Revenue (ttm) | 33.95B +6.1% |
| Net Income | 3.44B +51.7% |
| EPS | 3.94 +52.3% |
| Shares Out | n/a |
| PE Ratio | 19.74 |
| Forward PE | 13.80 |
| Dividend | 0.72 (2.12%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | n/a |
| Open | 33.81 |
| Previous Close | 33.81 |
| Day's Range | 33.81 - 33.81 |
| 52-Week Range | 33.50 - 40.88 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew Transcript: Investor update
Smith & Nephew is accelerating growth through innovation in wound care, sports medicine, and orthopedics, with a strong focus on robotics and efficiency for ambulatory surgery centers. Key platforms like PICO, REGENETEN, CARTIHEAL, and the Landmark knee system are driving clinical and operational advances, supported by robust clinical evidence and a growing ASC presence.
Smith & Nephew Slides: Investor update
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, ...
Cevian Capital II GP LTD Increases Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Increases Stake in Smith & Nephew PLC
Smith & Nephew PLC (SNN) Stock Up 3.1% and Still Undervalued -- GF Score: 86/100
Smith & Nephew PLC (SNN) Stock Up 3.1% and Still Undervalued -- GF Score: 86/100
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy with a price target of 1,230 GBp, down from 1,462 GBp. The firm sees limited near-term catalysts for a re-rating…
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy.
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform d...
Smith & Nephew (SNN) Joins Goldman Sachs' European Conviction List
Smith & Nephew (SNN) Joins Goldman Sachs' European Conviction List
Smith & Nephew added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Smith & Nephew to the firm’s European Conviction List as part of its monthly update. The company’s guidance reset brings an opportunity to revisit a name…
Smith & Nephew Slides: Investor presentation
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Smith & Nephew price target lowered to 1,550 GBp at Goldman Sachs
Goldman Sachs analyst Richard Felton lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,700 GBp and keeps a Buy rating on the shares. The firm…
Smith & Nephew price target lowered to $30 from $32 at Canaccord
Canaccord lowered the firm’s price target on Smith & Nephew to $30 from $32 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein
Bernstein lowered the firm’s price target on Smith & Nephew to $31.85 from $36.20 and keeps a Market Perform rating on the shares after the company provided a Q1 trading…
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Smith & Nephew and Four More Stocks See Action From Activist Investors
Smith & Nephew To Repurchase Up To $250 Mln Of Shares
(RTTNews) - Smith & Nephew PLC (SNN, SN.L), a medical technology company, said on Friday that it has inked a deal with Merrill Lynch International to repurchase up to $250 million of shares at $0.20 p...
Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,350 GBp from 1,300 GBp and keeps an Equal Weight rating on the shares. Th firm updated the company’s…
Smith & Nephew Earnings Call Transcript: Q1 2026
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
Smith & Nephew Slides: Q1 2026
Smith & Nephew has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Smith & Nephew Earnings release: Q1 2026
Smith & Nephew released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annu...
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...
Smith & Nephew price target lowered to $32 from $35 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model…
Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
Smith+Nephew announces further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its Cartiheal Agili-C Cartilage Repair Implant recently published in th...